Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma

Article Biochemistry & Molecular Biology

Interleukin-8: An evolving chemokine

Kouji Matsushima et al.

Summary: This article introduces the research history and related findings of interleukin-8 (IL-8), including the role of IL-8 in inflammation and cancer, as well as its potential as a therapeutic target.

CYTOKINE (2022)

Add to Collection

Article Pathology

Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma

Daisuke Kiyozawa et al.

Summary: Collecting duct carcinoma (CDC) is a rare subset of high-grade renal cell carcinoma (RCC), and there is overlap in the morphology with other renal tumors. This study reclassified invasive/infiltrating high-grade RCC and found that a combination of immunohistochemistry and molecular biological techniques is necessary for the diagnosis of invasive/infiltrating high-grade RCC.

HUMAN PATHOLOGY (2022)

Add to Collection

Article Oncology

Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma

Guangxi Sun et al.

Summary: This study conducted integrated genomic, epigenomic, and molecular analyses on 25 untreated primary FH-deficient RCCs, revealing low somatic mutation burden, frequent somatic copy-number alterations, and a CpG sites island methylator phenotype in these tumors. Clinical data showed that patients treated with immune checkpoint blockade-based therapy had significantly longer progression-free survival compared to those receiving antiangiogenic monotherapy.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance

Agata A. Bielska et al.

Summary: Not all Lynch-associated dMMR tumors have high TMB, and tumors with dMMR/TMB discordance may be resistant to immunotherapy. TMB evaluation could guide the use of immune checkpoint inhibitors, particularly in less-typical Lynch cancers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma

Gennady Bratslavsky et al.

Summary: The study found that genomic alteration patterns in collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) differ significantly from clear cell renal cell carcinoma (CCRCC). Targeted therapies for CDC and RMC appear limited, with rare opportunities to target alterations in receptor tyrosine kinase and MTOR pathways. Similarly, the low TMB and absence of MSI-High status in CDC and RMC suggest resistance to immunotherapies.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

Diego Kauffmann-Guerrero et al.

Summary: Inflammation status and cytokine profile can serve as additional biomarkers predicting response and survival in NSCLC patients treated with single agent ICIs. Patients with signs of pre-therapeutic inflammation showed lower response to ICI treatment, while those with elevated levels of IFN-gamma significantly benefited. Low systemic inflammation and high levels of IFN-gamma were characteristics of patients with long-term response to ICI treatment.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Pathology